AtriCure reported strong first quarter 2025 results with worldwide revenue increasing 13.6% year over year to $123.6 million. The company significantly improved its net loss, reducing it by $6.5 million year over year, and saw a substantial increase in Adjusted EBITDA, growing by $6.0 million year over year to $8.8 million.
Worldwide revenue grew 13.6% year over year to $123.6 million, or 14.1% on a constant currency basis.
Net loss improved by $6.5 million year over year, totaling $6.7 million for the quarter.
Adjusted EBITDA increased by $6.0 million year over year, reaching $8.8 million.
U.S. revenue increased 12.1% to $101.1 million, driven by key product lines including EnCompass clamp, cryoSPHERE MAX probes, and AtriClip Flex·Mini device.
AtriCure projects full year 2025 revenue between $517 million and $527 million, Adjusted EBITDA between $44 million and $46 million, and adjusted loss per share between $0.50 and $0.55, with modest cash flow generation expected.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance